ArticleWorld journal of surgery2026
Comparative Study of Myocutaneous Latissimus Dorsi Flap Breast Reconstruction With Implant Versus Lipofilling: Complication Rates and Risk Factors.
Article in World journal of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is the most prevalent malignancy among women globally, and mastectomy often forms a critical part of its treatment. Breast reconstruction is an important aspect of post-mastectomy care, contributing to improved psychological well-being and quality of life. This study compares the outcomes of two distinct Latissimus Dorsi (LD) flap reconstruction techniques: one utilizing implant augmentation (LD-I) and the other employing autologous fat graft (lipofilling) for volume restoration (LD-L).
methodsA retrospective cohort study was conducted, analyzing 116 patients who underwent breast reconstruction with either the LD-I or LD-L technique between 2013 and May 2024. Data was collected from two centers in Brazil. The primary outcome was the rate of major complications, defined as those requiring surgical re-intervention or hospital readmission. Secondary outcomes included the incidence of early (≤ 6 months) and late (> 6 months) complications and the correlation of clinical characteristics in regards to the complications, such as comorbidities and vices.
resultsThe study population comprised 50 patients in the LD-I group and 66 patients in the LD-L group. The mean age of patients was approximately 50 years in both groups. There were no significant differences between the groups regarding oncologic characteristics, including tumor stage, histological subtype, and receipt of neoadjuvant or adjuvant therapies. While the overall rate of major complications was not statistically different between the two groups (18% LD-I vs. 7.6% LD-L, p = 0.079), specific complications varied. The LD-I group exhibited a significantly higher rate of early infections (20% vs. 6.1%, p = 0.023) and a greater incidence of late reconstruction loss due to implant-related issues (10% vs. 0%, p = 0.013).
conclusionBoth LD-I and LD-L techniques provide viable options for breast reconstruction. However, the LD-L technique demonstrated a lower risk of infection and reconstruction loss in this cohort. These findings suggest that LD-L may offer a favorable alternative for minimizing specific complications and improving long-term outcomes in post-mastectomy breast reconstruction. However, these findings should be analyzed with caution and further prospective, randomized studies with larger sample sizes are warranted to confirm these observations and to identify specific patient subgroups that may benefit most from each technique.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.